Genexine Inc. has licensed out its proprietary long-acting immuno-oncology drug HyLeukin to I-MAB Biopharma for $548m plus sales royalties, marking the South Korean biotech company's first immuno-oncology deal.
HyLeukin, also known as GX-I7, is an immuno-oncology agent comprising an optimally engineered Interleukin-7 (IL-7) molecule based on Genexine’s proprietary...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
